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Abstract: In an open-chest porcine model, we examined whether myocardial pharmacological conditioning at the time of reperfu-
sion with low-dose insulin or insulin-like growth factor 2 (IGF2), not affecting serum glucose levels, could reduce infarct size
and improve functional recovery. Two groups of anaesthetized pigs with either 60 or 40 min. of left anterior descending artery
occlusion (total n = 42) were randomized to receive either 0.9% saline, insulin or IGF2 infusion for 15 min., starting 5 min.
before a 180-min. reperfusion period. Repeated fluorescent microsphere injections were used to confirm ischaemia and reperfu-
sion. Area at risk and infarct size was determined with Evans blue and triphenyltetrazolium chloride staining. Local myocardial
function was evaluated with multi-layer radial tissue Doppler strain and speckle-tracking strain from epicardial echocardiography.
Western blotting and TUNEL staining were performed to explore apoptosis. Infarct size did not differ between treatment groups
and was 56.7  6.8%, 49.7  9.6%, 56.2  8.0% of area at risk for control, insulin and IGF2 group, respectively, in the
60-min. occlusion series. Corresponding values were 45.6  6.0%, 48.4  7.2% and 34.1  5.8% after 40-min. occlusion.
Global and local cardiac function did not differ between treatment groups. No differences related to treatment could be found in
myocardial tissue cleaved caspase-3 content or the degree of TUNEL staining. Reperfusion therapy with low-dose insulin or with
IGF2 neither reduced infarct size nor improved function in reperfused myocardium in this in vivo porcine model.
In experimental studies, administration of different pharmaco-
logical agents during myocardial reperfusion has demonstrated
promising results decreasing infarct size; clinically results are
variable [1]. Both necrosis and apoptosis play a part in myo-
cardial cell death during ischaemia–reperfusion [2], and apop-
totic cell death could primarily be a consequence of
reperfusion [3,4]. Inhibition of apoptosis decreases infarct size
and improves regional contractile function [5].
Experimentally, glucose–insulin–potassium (GIK) infusion
and low-dose insulin alleviates myocardial damage after myo-
cardial ischaemia–reperfusion [6,7]. However, in patients with
suspected acute coronary syndrome, pre-hospital GIK infusion
did not reduce progression to myocardial infarction and
30-day mortality [8]. Nevertheless, in a cohort of patients
evaluated with technetium Tc 99m sestamibi imaging at
30 days after infarction, the infarct size was reduced for those
who received GIK treatment. In isolated rat hearts, insulin
administered for a short time period at reperfusion reduces
apoptosis and myocardial infarct size by stimulating the phos-
phatidylinositol 30-kinase (PI3-kinase)–Akt-dependent reperfu-
sion injury salvage kinases (RISK) pathway [9].
This study examined whether RISK pathway up-regulation
with low-dose insulin or IGF2, not affecting serum glucose
levels and metabolism, administered in the early reperfusion
period, could reduce reperfusion injury in an in vivo pig
model. Myocardial cell death and infarction develops as a
wave front from the subendocardium towards the subepicardi-
um [10]. Therefore, myocardial infarct size and apoptotic
activity were studied together with global and regional myo-
cardial function and perfusion with focus on transmural differ-
ences between myocardial wall layers.
Materials and Methods
Anaesthesia. Experiments were performed in accordance with the
European Communities Council Directive of 2010 (63/EU) and
approved by the Norwegian State Commission for Laboratory Animals
(Project 20113923). Sixty-seven Norwegian Landrace pigs of either
gender, weighing 43  4 kg (S.D.), were fasted overnight and pre-
medicated with i.m. ketamine (20 mg/kg), diazepam (10 mg) and
atropine (1 mg). Mask ventilation with 3% isoflurane allowed
cannulation of two ear veins for induction of anaesthesia with loading
doses of fentanyl (0.02 mg/kg), midazolam (0.3 mg/kg), vecuronium
(0.2 mg/kg) and pentobarbital (15 mg/kg), followed by continuous
infusion of fentanyl (0.02 mg/kg/hr), midazolam (0.3 mg/kg/hr),
vecuronium (0.1 mg/kg/hr) and pentobarbital (4 mg/kg/hr) [11].
Ventilation (Julian, Dr€ager, L€ubeck, Germany) with nitrous oxide (56–
58%) and oxygen was commenced on mask and continued through a
tracheotomy. For 30 min., 15 ml/kg/hr glucose 5% was given as fluid
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substitution followed by Ringer’s acetate for the rest of the
experiment, both solutions with 20 mM KCl added.
Animal preparation. The right femoral artery and vein were
cannulated for blood sampling. Urine was drained with a bladder
catheter and rectal temperature monitored. Midline sternotomy and
pericardiotomy exposed the heart. Heparin 125 IU/kg was
administered, and central venous and pulmonary artery pressures
(SensoNor, Horten, Norway) and cardiac output (Vigilance-2;
Edwards Lifesciences Inc., Irvine, CA, USA) were assessed with a
Swan-Ganz continuous cardiac output catheter (139H-7,5F; Edwards
Lifesciences Inc.) advanced through the mammary vein. Central aortic
and left ventricular pressures were monitored with pressure-tip
catheters (Millar MPC-500, Houston, TX, USA) advanced through the
left internal mammarian artery and the apex of the heart. Variables
were continuously sampled and digitized (Ponemah ACQ7700; DSI,
St. Paul, MN, USA). The left atrium was cannulated for microsphere
injections and for infusions of physiological saline, insulin or IGF2.
The left anterior descending coronary artery (LAD) was dissected free
in the middle segment allowing placement of a loose silk ligature and
a vascular clamp. After instrumentation (1½-2 hr), a new bolus of
heparin 125 IU/kg was given and animals were allowed to stabilize
for 10 min. before measuring baseline variables.
Experimental protocols. Separately in two consecutive experimental
series, animals were block-randomized in blocks of three with seven
animals allocated into each treatment group. Two experimental series
with either 60 min. (Occl-60) or 40 (Occl-40) min. of LAD occlusion,
followed by 180-min. reperfusion were performed. Infusion of either
saline, insulin 2 mU/kg or IGF2 2 lg/kg dissolved in saline was
commenced via the left atrial catheter 5 min. before start of
reperfusion and continued for 10 min. into the reperfusion period. In
all animals, a total amount of 2 mg/kg lidocaine was given i.v. as
small repeated boluses to handle the frequently observed arrhythmias
during occlusion and early reperfusion. Ventricular fibrillation was
electroconverted. No other anti-arrhythmic interventions were allowed.
Additional heparin 125 IU/kg was administered at reperfusion, and
after 3 hr, the animals were killed with intracardiac saturated KCl.
The LAD ligature was tightened, the aorta partially cross-clamped and
2% Evans blue injected into the aortic root, staining the myocardium
outside the area at risk (AAR). The hearts were quickly removed for
tissue sampling and infarct quantification.
Myocardial tissue blood flow rate was estimated with 15-lm fluo-
rescent microspheres (Dye-Trak “F”; Triton Technology Inc., San
Diego, CA, USA) at baseline, 10 min. after start of occlusion, and
15 min. and 180 min. after start of reperfusion. Simultaneously, arte-
rial blood gases (AVL Optil, AVL Scientific Corporation, Roswell,
GA, USA) and s-glucose were registered. Serum troponin T was
obtained at baseline and after three hours of reperfusion.
Fifteen animals were anaesthetized and instrumented but without
occlusion of the coronary artery. Corresponding amounts of insulin
(n = 5), IGF2 (n = 5) or saline (n = 5) were infused intra-atrially for
15 min. These hearts were then arrested and removed, and tissue sam-
ples were harvested and studied for phosphorylation of Akt.
Data acquisition and analysis. Haemodynamic variables were
analysed for baseline, 10 min. after start of occlusion and 15, 30 and
thereafter every 30 min. until 180 min. of reperfusion. Left ventricular
peak systolic (LVSPmax) and end-diastolic (LVEDP) pressures, peak
positive (LV-dP/dtmax) and peak negative (LV-dP/dtmin) of first
derivate of left ventricular pressure together with cardiac index (CI)
and mean aortic pressure (AOPmean) were noted. Epicardial left
ventricular short-axis and apical long-axis echocardiographic views
(including the region of the myocardium rendered ischaemic) were
recorded at baseline, and 15 min. and 180 min. after start of
reperfusion (Vivid E9, GE Vingmed Ultrasound, Horten, Norway).
The left ventricular anterior wall was analysed (EchoPac PC BT11,
GE Vingmed Ultrasound) for peak systolic radial tissue Doppler strain
(TDI) in the subendocardial, mid-myocardial and subepicardial wall
layers and calculated as mean of three consecutive cardiac cycles.
Short-axis and apical long-axis B-mode views were analysed for
transmural peak systolic circumferential and longitudinal speckle-
tracking echocardiography (STE) strain in six segments also as the
mean of three consecutive cardiac cycles [12]. Strain values were
obtained with spatial smoothing set to minimum. The diastolic and
systolic wall thicknesses were measured at the start of the QRS
complex and at aortic valve closure defined from pulsed wave
Doppler recordings in the aortic annulus, and systolic wall thickening
was calculated.
The hearts were removed and weighed. The left ventricle (LV) was
cut into approximately 5-mm-thick slices. Each slice up to the level of
the silk ligature on LAD was weighed separately, and the remaining
LV was weighed en bloc. Two slices were used for tissue samples,
and all the other slices including area at risk (AAR) were scanned
(Epson ScanV500) on both sides, then incubated in 1% solution of
2,3,5-triphenyltetrazolium chloride (TTC) staining for 15 min. at 37°C
and dipped in paraformaldehyde before a second scanning. Scans were
analysed with computerized planimetry (Adobe Photoshop CS5
Extended, version 12.0, San Jose, CA, USA), and the extent of
infarcted area (IA) (non-TTC-stained) versus AAR (Evans blue nega-
tive) and AAR versus total LV was quantified transmurally, but also
separately in the subendocardial, mid-myocardial and subepicardial
thirds of the LV wall.
Tissue samples from the subendocardial, mid-myocardial and
subepicardial thirds of both the LV anterior and posterior wall were
Fig. 1. A representative immunoblot (upper part) of phosphorylated
Akt (p-Akt), total Akt and glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) in left ventricular myocardium from animals without LAD
occlusion with 15 min. infusion of saline (CON), insulin (INS) or
IGF2. Densitometric analysis of samples from subendocardial (Endo),
mid-myocardial (Mid) and subepicardial (Epi) wall layers (control
n = 5, insulin n = 5, IGF2 n = 5), normalized to an internal control
present on each blot. pAkt as a fraction of total Akt in the same sam-
ple. IGF2 = insulin-like growth factor 2.
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isolated, snap-frozen in liquid nitrogen and stored at 80°C. Corre-
sponding tissue samples were immersed in paraformaldehyde, washed
in ethanol, embedded in paraffin and sectioned for histology. Tissue
samples from the three myocardial wall layers were also analysed for
tissue blood flow rate and water content.
Cleaved caspase-3 (22 kDa) (BD-Pharmingen, San Diego, CA,
USA) and GAPDH (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) were determined in the three wall layers of the LV anterior
wall. Homogenization, protein quantification, sample preparation
(40 lg/lane) and electrophoresis were performed as previously
described Jonassen et al. [9]. Densitometric analyses were performed
using Quantity One software (Bio-Rad, Hercules, CA, USA). The den-
sitometric readings from each sample were normalized to a control
sample included on all blots.
Terminal deoxynucleotidyl transferase-mediated 2
̓
-deoxyuridine 5
̓
-
triphosphate nick end labelling (TUNEL) assay was performed to
detect and quantify apoptosis. The number of apoptotic nuclei in the
region within the AAR close to intact myocardium and in the non-is-
chaemic posterior wall was counted. For each section, coded for the
investigator, quantification of the number of apoptotic nuclei in an
area of 1 million of square pixels (1Mpx2) was performed.
Statistical analysis. Statistical analyses were performed (SPSS 20 Inc,
Chigaco, IL, USA) and values reported as mean  S.E.M. unless
otherwise noted. The two study series (Occl-60 and Occl-40) were
analysed separately. Baseline variables and variables recorded 10 min.
after LAD occlusion were compared between groups by one-way
analysis of variance. Haemodynamic variables, blood flow rate and
strain after reperfusion with or without baseline included were
analysed by two-way RM-ANOVA with time as within-factor and
treatment (control/insulin/IGF2) as grouping factor. Wall layers in the
same heart were the related (within) factor for tissue caspase-3, the
number of apoptotic cells (after logarithmic transformation) and layer-
specific infarct size. If Mauchly’s test for sphericity was violated
(p < 0.05), the Greenhouse–Geisser adjustment of degrees of freedom
was selected for evaluation of main effects. A significant interaction
effect called for new ANOVAs for simple main effects. Cell means were
finally compared with Newman–Keuls multiple contrast tests when
appropriate. A p value <0.05 was considered statistically significant.
Results
Before intervention.
Ten animals (six in Occl-60 and four in Occl-40 series) devel-
oped irreversible ventricular fibrillation within 20–30 min.
after LAD occlusion and were replaced. In the animals with-
out LAD occlusion, there was an increase in phosphorylated
Akt relative to total Akt with infusion of insulin or IGF2
(p < 0.05 for all wall layers) compared to the controls with
saline infusion (fig. 1).
There were no differences in arterial blood gases or serum
electrolytes either between groups or between series. Serum
glucose was equal between groups (a grand mean
6.4  0.3 mM at baseline and 5.9  0.2 mM after 10 min. of
LAD occlusion). Troponin T at baseline was 34.0  11.9 ng/l
in the Occl-60 series and 25.8  4.0 ng/l in Occl-40 series.
The haemodynamic variables at baseline and at 10 min. after
LAD occlusion did not differ significantly between groups in
either series, except for a slightly increased baseline CI in the
Occl-40 insulin group (fig. 2). At baseline, regional myocar-
dial function in the anterior LV wall did not differ between
treatment groups as judged by the three-layer radial peak sys-
tolic TDI strain, circumferential and longitudinal STE strain
and wall thickening (figs. 3 and 4, table 1). Three-layer TDI
strain demonstrated the typical transmural heterogeneity in
non-ischaemic myocardium with lower radial strain values in
outer compared with inner wall layers. Myocardial tissue
blood flow rate was similar for all groups at baseline and
demonstrated severe and transmural ischaemia affecting all
wall layers in the anterior wall (AAR) during LAD occlusion
(fig. 4). In the Occl-60 series, the non-ischaemic posterior wall
tissue blood flow rate was 0.90  0.05, 0.85  0.04 and
0.85  0.05 ml/min per g subendocardially, mid-myocardially
and subepicardially, respectively. Corresponding values in the
Table 1.
End-diastolic wall thickness in the ischaemic (AntED-) and non-ischaemic (PostED-) region before, and 15 and 180 min. after reperfusion following
60 and 40 min. of LAD occlusion. Mean  S.E.M. for seven animals in each group.
Baseline 150 rep. 1800 rep. RM-ANOVA
600 LAD-occl:
AntED-CON (mm) 6.86  0.22 15.00  0.95 12.81  1.07 pw < 0.001
AntED-INS (mm) 7.05  0.29 12.71  1.29 11.95  1.34 pg = 0.66 Baseline 6¼ 150 6¼ 1800
AntED-IGF2 (mm) 7.52  0.38 13.71  0.98 12.24  1.00 pi = 0.37
PostED-CON (mm) 7.19  0.23 8.19  0.22 8.19  0.24 pw < 0.001
PostED-INS (mm) 7.33  0.26 8.76  0.21 8.71  0.34 pg = 0.20 Baseline 6¼ 150 = 1800
PostED-IGF2 (mm) 7.95  0.25 8.81  0.33 8.38  0.25 pi = 0.19
400 LAD-occl:
AntED-CON (mm) 6.71  0.26 13.67  0.69 12.10  0.51 pw < 0.001
AntED-INS (mm) 6.90  0.29 12.05  1.40 11.48  1.15 pg = 0.68 Baseline 6¼ 150 6¼ 1800
AntED-IGF2 (mm) 7.00  0.13 11.81  0.87 11.57  0.94 pi = 0.43
PostED-CON (mm) 7.05  0.26 7.76  0.38 7.62  0.31 pw = 0.005
PostED-INS (mm) 6.90  0.27 7.74  0.29 7.81  0.46 pg = 0.81 Baseline 6¼ 150 = 1800
PostED-IGF2 (mm) 7.43  0.27 8.00  0.31 7.67  0.44 pi = 0.78
AntED and PostED = anterior and posterior left ventricular end-diastolic; CON, INS and IGF2 = control, insulin and insulin-like growth factor 2
group, respectively; pw, pg and pi = probability for significance for the within factor (time), grouping factor and interaction between time and
group, respectively.
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Occl-40 series were 0.97  0.04, 0.87  0.04 and
0.92  0.03 ml/min per g.
After reperfusion.
In the Occl-60 series, there were no differences between treat-
ment groups regarding LVSPmax, heart rate (HR) and CI early
after reperfusion (fig. 2, left). LVSPmax and CI decreased
gradually over time in all groups from 15 to 180 min. of rep-
erfusion (pw < 0.001) with no difference between interven-
tions. LVEDP was low (pg < 0.009) in control animals
compared with both intervention groups. HR, LV-dP/dtmax,
LV-dP/dtmin and AOPmean did not change. In the Occl-40
series, haemodynamic and global cardiac variables did not
differ between groups, LVSPmax decreased slightly
(pw = 0.017) over time, and the other haemodynamic variables
were unchanged (fig. 2, right).
At early reperfusion, radial TDI strain in the subendocardi-
um was close to zero or negative in all groups and remained
unchanged 3 hr after reperfusion (fig. 3). In the mid-myocar-
dial and subepicardial layers, the TDI strain declined further
from early to late reperfusion in the Occl-60 animals, whereas
in Occl-40 series, there was no difference from early to late
reperfusion. Peak systolic circumferential STE strain in the
anteroseptal segment (within the AAR) in Occl-60 series was
reduced (less negative) at early reperfusion and was
unchanged after 180-min. reperfusion with no differences
Fig. 2. Haemodynamic variables in pigs with 60 and 40 min. of LAD occlusion and 180 min. of reperfusion. HR = heart rate; LVSPmax = left
ventricular peak systolic pressure; LVEDP = left ventricular end-diastolic pressure; CI = cardiac index. CON = saline; INS = insulin; IGF2 = insu-
lin-like growth factor 2. Mean values (S.E.M.) for baseline (base), 10 min. into the occlusion period (10’Occl) and after reperfusion. pw, pg and
pi = probabilities for within, group and interaction effect from RM-ANOVA for the reperfusion period.
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between treatment groups (fig. 4). Similar results were also
obtained in Occl-40 series. Longitudinal STE strain was low
and unchanged in the apicoanterior segment (within the AAR)
in all groups in both series, both at early and late reperfusion.
Left ventricular anterior wall thickening decreased in all
groups from baseline (grand mean 49.2  1.9% in Occl-60
series and 51.2  2.5% in Occl-40 series) to nearly zero or to
negative values both at early and late reperfusion.
Tissue blood flow, wall thickness and oedema.
Successful reperfusion and hyperaemia was observed macro-
scopically in the AAR region immediately after releasing the
vessel clamp on the LAD. This was also confirmed with the
third microsphere injection 15 min. after reperfusion in all
groups and wall layers at early reperfusion compared with the
corresponding baseline values (fig. 5). At late reperfusion, tis-
sue blood flow rate was decreased to levels significantly lower
than at baseline (pw < 0.01) with no differences between
treatment groups. After LAD occlusion and reperfusion, flow
rates in the non-ischaemic posterior wall did not change.
Tissue water content increased in the anterior wall of AAR
compared with the posterior non-ischaemic myocardium. End-
diastolic wall thickness doubled (table 1) at early reperfusion
compared with baseline and decreased slightly at 180 min.
after reperfusion in all groups. Tissue oedema (% increase in
water content in the anterior versus corresponding posterior
LV wall layer) was increased in the control and insulin groups
compared with IGF2 the Occl-60 series in the subendocardial
(3.3  0.4% and 3.5  0.3% versus 1.9  0.3%) and in the
mid-myocardial (4.1  0.4% and 3.1  0.5% versus
2.8  0.6%) wall layers (p < 0.05 for all comparisons). In the
subepicardium, there was no significant oedema in the IGF2
group, compared with 3.6  0.5% and 3.9  0.4% in control
and insulin groups. In Occl-40 series, there was a significant
tissue oedema in the anterior wall, but with no differences
between groups and wall layers (grand mean 3.4  0.2%).
Apoptosis.
The myocardial content of cleaved caspase-3 was low in
ischaemic/reperfused myocardium in the Occl-60 series
Fig. 3. Radial peak systolic strain by tissue Doppler imaging in the area at risk of the left ventricular anterior wall at baseline and at 15 and
180 min. of reperfusion (rep) after LAD occlusion. Bars are mean + S.E.M. (n = 7). CON = saline; INS = insulin; IGF2 = insulin-like growth fac-
tor 2. #p < 0.05 versus 150 reperfusion (pooled means).
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compared with Occl-40 series. There was no significant differ-
ence between treatment groups or wall layers, neither in the
Occl-60 nor in the Occl-40 series (fig. 6, top). In the Occl-60
series, there was a transmural gradient with decreasing density
of TUNEL-stained nuclei from the subendocardium to the sub-
epicardium (pw < 0.001), but with no differences between
treatment groups (pg = 0.44) and no significant interaction
effect (pi = 0.86) (fig. 6, middle). In the Occl-40 series, no
layer (pw = 0.21) or group (pg = 0.29) difference was found.
Infarct size.
Area at risk varied from 13.7% to 17.6% of left ventricular
mass, with no differences between the treatment groups. In
animals in Occl-60 series, myocardial infarct size (IA/AAR)
was 56.7  6.8%, 56.2  8.0% and 49.7  9.6% for the con-
trol, insulin and IGF2 group, respectively. Corresponding val-
ues were 45.6  6.0%, 48.4  7.2% and 34.1  5.8% in the
Occl-40 series. There were no significant differences between
treatment groups in either series. Layer-specific analyses of
the extent of infarction revealed no significant differences
between treatment groups (fig. 5, bottom).
Glucose and troponin-T.
Serum glucose values remained unchanged at early reperfu-
sion compared with baseline, but were slightly decreased after
180 min. of reperfusion in all groups, averaging 5.4  0.4
and 6.1  0.2 mM in Occl-60 and Occl-40 series, respec-
tively. Troponin T was 1584  601 ng/l, 2674  444 ng/land
3156  646 ngl for control, insulin and IGF2 group, respec-
tively, in animals with 60-min. LAD occlusion and
1642  159 ngl, 1807  219 ng/l and 1432  218 ng/l for
control, insulin and IGF2 group, respectively, after 40 min. of
LAD occlusion. There were no significant differences between
treatment groups for troponin T levels.
Discussion
Several experimental studies have demonstrated a cardiopro-
tective nature of insulin and insulin-like growth factors by
stimulating the PI3-kinase–Akt pathway [6,7,9,13]. This path-
way can modulate the apoptotic cascade, reduce lethal reperfu-
sion injury and thus reduce infarct size after ischaemia–
reperfusion. In the present study, reperfusion therapy with
low-dose insulin or IGF2 did not reduce myocardial infarct
size when measured after 3 hr of reperfusion, following 60 or
40 min. of LAD occlusion.
We aimed at stimulating the PI3-kinase–Akt pathway without
altering the serum glucose levels. In animals without LAD
occlusion, the infusion of low-dose insulin or IGF2 for 15 min.
increased the levels of phosphorylated Akt relative to total Akt
in the myocardium by 1.5 to 2, thus demonstrating an activation
of PI3-kinase–Akt signalling pathway (fig. 1). In fasting pigs, a
corresponding dose of intracoronary insulin (1.8-2.3 mU/kg)
was administered without causing severe hypoglycaemia [14]
and was shown to stimulate Akt phosphorylation [15].
Fig. 4. Peak systolic strain by speckle-tracking echocardiography (STE) in circumferential and longitudinal direction at baseline and 15 and
180 min. after reperfusion. Abbreviations as in fig. 3.
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The amount of IGF2 administered, 2 lg/kg, was decided
from our previous study demonstrating an anti-apoptotic
effect when administered intracoronarily together with blood
cardioplegia, resulting in a total amount of 0.252 lg/kg [16].
Timing of administration was based on studies in isolated rat
heart models showing that a single dose of insulin must be
administered at the time of reperfusion to reduce infarct size;
a delay of 15 min. will abolish the effect [9]. Protocols with
60 and 40 min. of LAD occlusion followed by reperfusion
were based on previous studies in pigs demonstrating a cut-
off time of approximately 50 min. for an acute coronary
occlusion before reperfusion must occur; prolonged occlusion
time results in an irreversible ischaemic trauma making reper-
fusion interventions ineffective [10]. However, there are also
comparable experiments in pigs reporting favourable effects
of reperfusion interventions after even 75- and 90-min.
coronary occlusion [13,17].
This study demonstrates no obvious signs of infarct size
reduction when administering insulin or IGF2 at the onset
of reperfusion, either after 60 or 40 min. of LAD occlusion
despite the activation of RISK pathway. Exenatide, a
glucagon-like peptide, reduced apoptosis and infarct size,
and improved myocardial function in pigs when adminis-
tered repeatedly for three days [17]. The prolonged time of
elevated insulin levels and a long observation time before
estimating infarct size and cardiac function could explain the
difference compared with the present study. One single low
dose of IGF1 administered as late as 2 hr after reperfusion
in a chronic pig model reduced infarct size and improved
cardiac function together with reduced apoptosis [13]. It is
speculated whether IGF1 contributed to the stimulation of
cardiomyogenesis and angiogenesis. In a canine study, the
reduction in infarct size and improved cardiac function by
administering low-dose insulin at reperfusion was compara-
ble to GIK infusion for 4 hr starting 10 min. before reperfu-
sion [7]. Compared with dogs, the collateral blood flow rate
in the myocardium is low in pigs (fig. 5) [18]. Recently, it
has been demonstrated in pigs that infarct size reduction
after mechanical post-conditioning is independent of RISK
phosphorylation [19] and the reperfusion itself can
Fig. 5. Tissue blood flow rate in the left ventricular anterior wall in subendocardial, mid-myocardial and subepicardial wall layers after 60 (left)
and 40 min. (right) of LAD occlusion followed by reperfusion. Abbreviations as in fig. 3. *Pooled mean different from pooled mean at baseline;
# Pooled mean different from pooled mean at 150 rep (p < 0.01 for all).
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phosphorylate this pathway without resulting in a decreased
infarct size.
The wavefront phenomenon with myocardial cell death
extending both laterally and from the subendocardium to the
subepicardium after an acute coronary occlusion has been
described clinically and in different experimental animal mod-
els, also in pigs [10]. It is thus reasonable to assume that sal-
vageable myocardium is predominantly found in the
subepicardium of the area at risk. The myocardial wall was
severely ischaemic after LAD occlusion, irrespective of wall
layer (fig. 5), but with less extensive development of infarc-
tion in the subepicardium where infarct size (% of area at risk)
averaged 40.8  0.1% in the Occl-60 and 26.6  0.1% in the
Occl-40 series (fig. 6). However, we could not demonstrate
any significant reduction in infarct size by insulin or IGF2 in
any wall layer. Furthermore, the degree of apoptosis, here
evaluated by tissue content of cleaved caspase-3 and TUNEL
staining, was not affected by the interventions with insulin or
IGF2.
The present study is an acute model with reperfusion for
three hours after the ischaemic event. Previously, we have
shown that IGF2 added to repeated cold blood cardioplegia
improved contractility in the LV wall after 60 min. of cardiac
arrest [16]. In the present study, no improvement of post-is-
chaemic function in reperfused myocardium was demonstrated,
irrespective of the myocardial wall layer (figs. 3 and 4). The
circumferential STE strain reflects function in mid-myocardial
fibres oriented circumferentially, whereas the longitudinal STE
strain predominantly describes subendocardium with longitudi-
nal fibres [12]. Neither the radial multilayer TDI strain nor the
circumferential or longitudinal STE strain showed functional
differences between groups. The persistent reduction in myo-
cardial function could partly be explained by myocardial stun-
ning, lasting from several hours to days after severe ischaemia
and reperfusion [20]. This would conceal any favourable effect
of the anti-apoptotic interventions in the present study.
Stunned myocardium is viable [21]. As the development of
infarction in the AAR was not affected by insulin or by IGF2,
one might not expect any functional differences between treat-
ment groups, even with prolonged observation. However, a
difference between animals with 40 and 60 min. of LAD
occlusion could have been detected. This could explain why
CI and radial TDI strain decreased slightly between 15 min.
and 180 min. of reperfusion in the Occl-60 series,
but remained unchanged in animals with 40 min. of LAD
occlusion.
Fig. 6. Cleaved caspase-3 (~22 kDa), number of apoptotic nuclei (TUNEL staining) and infarct size in wall layers of reperfused myocardium in
animals with 60 and 40 min. of LAD occlusion followed by 180-min. reperfusion. Bars are mean + S.E.M., box plots presents median with 25 and
75 percentiles, single experiments and mean (squares)  S.E.M. AU = arbitrary units; IA/AAR = infarct area/area at risk; CON = saline;
INS = insulin; IGF2 = insulin-like growth factor 2; Endo, Mid, Epi = subendocardial, mid-myocardial and subepicardial thirds of the left ventricu-
lar wall.
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Previous studies have demonstrated a vasodilatory effect of
insulin via activation of Akt, leading to phosphorylation of
endothelial nitric oxide synthase (eNOS) [6]. This increases
production of endogenous nitric oxide (NO) resulting in vaso-
dilatation and increased myocardial perfusion. Coronary endo-
thelial apoptosis and dysfunction was reduced and NO
production increased in a canine model after treatment with
GIK, but not with glucose–potassium alone [22]. In the pres-
ent study, the hyperaemic response at reperfusion was not
affected by insulin or IGF2 (fig. 5).
Limitations
The present in vivo pig model could be representative for a
subgroup of previously healthy patients with an acute coro-
nary occlusion and STEMI eligible for acute PCI. However,
in many patients with STEMI, the acute coronary occlusion
is a consequence of a long history of ischaemic heart disease
with development of collateral circulation and thus a larger
potential for myocardial salvage. In similar in vivo models,
beneficial effects are demonstrated if the reperfused myocar-
dium is exposed to the anti-apoptotic agent, being either insu-
lin, IGF1 or IGF2, for a long time period after reperfusion
[17,23]. In the present study, the amount of insulin or IGF2
may not be fully optimized to effectively activate anti-apopto-
tic pathways and thus reducing reperfusion injury and myo-
cardial stunning. However, as intended, an additional effect
related to glucose metabolism and potassium was not
observed.
In conclusion, we could not demonstrate any signs of infarct
size reduction or improved regional function when administer-
ing low-dose insulin or IGF2 at early reperfusion after 60 and
40 min. of LAD occlusion in an in vivo pig model. Neither
insulin nor IGF2 reduced apoptotic activity measured as tissue
content of activated caspase-3 or the number of apoptotic
myocytes in reperfused myocardium.
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